Drug intelligence / Profile preview

EPAX Evolve 05

Development stage: Unknown
Lead developer: Epax
Administration: Oral

Overview

EPAX Evolve 05 is a marine omega-3 concentrated oil, specifically a very long chain polyunsaturated fatty acid (VLC-PUFA) product. It is designed to support healthy aging, vision, skin health, muscle strength, bone health, and male fertility by replenishing VLC-PUFA levels, which naturally decline with age. It contains approximately 10 times more VLC-PUFAs than standard fish oil.

Brand names: EPAX Evolve 05

Beyond the preview

Go deeper on EPAX Evolve 05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPAX Evolve 05.

Explore the full profile